KK

Kai Kim

Chief Business Officer & Chief Finance Officer at ILIAS Biologics Inc.

Kai Kim has a diverse work experience spanning several industries. In 2023, they joined ILIAS Biologics Inc. as the Managing Director and Head of the Strategic Planning Group. Before that, from 2022 to 2023, they served as the Vice President of Strategy Business Development at ipscent. From 2020 to 2022, Kai worked at Medinno as the Executive Director and Head of BD and Management.

Prior to that, in 2019, they held two roles at Innovation @ UGA, first as the Startup Development Manager from August to December, and then as the Licensing Manager from January to April. In 2013, Kai joined Samsung Medical Center as the General Manager for the Planning and General Surgery Department, and they stayed in this position until 2018.

Before that, from 2008 to 2013, Kai worked at the KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE (KHIDI), holding multiple roles including Senior Researcher, Team Leader of R&D Policy Planning, Researcher, and Team Leader of Translational Research Support.

Kai Kim obtained a Bachelor's degree in Biotechnology and Environmental Science from Korea University, which they attended from 1996 to 2003. Kai then pursued a Master of Dentistry degree at Seoul National University from 2003 to 2008. After completing their master's degree, Kai Kim enrolled at Korea National Open University from 2008 to 2010, where they earned a Bachelor of Management degree. Finally, they went back to Seoul National University to pursue a Doctor of Philosophy for Public Administration, specializing in Health Policy and Management, from 2011 to 2018.

Location

Daejeon, Republic of Korea

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


ILIAS Biologics Inc.

2 followers

At ILIAS Biologics, they dedicate themselves to the development of paradigm-shifting advances in human medicine. Their platform technology, EXPLOR, makes it possible to load large therapeutic molecules into exosomes, and they are actively developing various therapeutic exosomes, Exo-Targets, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.


Industries

Employees

51-200

Links